高雄醫學大學圖書館 |

Cancer drug design and discovery

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Cancer drug design and discovery/ edited by Stephen Neidle.
other author:	Neidle, Stephen.
Published:	New York, NY :Academic Press, : 2008.,
[NT 15000922]:	1st ed.
Description:	xv, 473 p., [27] p. of plates :ill. (some col.) ; : 27 cm.;
基督教聖經之智慧書導讀 :	The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories.
Subject:	Antineoplastic agents - Development. -
Online resource:	An electronic book accessible through the World Wide Web; click for information
ISBN:	9780123694485

Cancer drug design and discovery
Cancer drug design and discovery[electronic resource] /edited by Stephen Neidle. - 1st ed. - New York, NY :Academic Press,2008. - xv, 473 p., [27] p. of plates :ill. (some col.) ;27 cm.

Includes bibliographical references and index.

Section I. Basic Principles -- 1. Modern cancer drug discovery: Integrating targets, technologies and treatments -- 2. Preclinical pharmacology and in vivo models -- 3. Clinical trial designs for more rapid proof-of-principle and approval -- Section II. Methodology -- 4. Structural biology and anticancer drug design -- 5. Natural product chemistry and cancer drug discovery -- 6. Pharmacokinetics & ADME optimization in drug discovery -- Section III. Drugs in the clinic and laboratory -- 7. Temozolomide: from cytotoxic to molecularly-targeted agent -- 8. Camptothecins for drug design, cancer cell death and gene targeting -- 9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer -- Section IV. New Agents -- 10. Targeting inactive kinases: structure as a foundation for cancer drug discovery -- 11. Cell cycle inhibitors in cancer: current status and future directions -- 12. Inhibition of DNA repair as a therapeutic target -- 13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways -- 14. Heat shock protein-90-directed therapeutics and target validation -- 15. Inhibitors of tumour angiogenesis -- 16. The biology and oncology of RAFERK signalling P53 as a therapeutic target -- Section V. The reality of cancer drugs in the clinic -- 17. Cancer drug resistance -- 18. Failure Modes in Anticancer Drug Discovery and Development.

The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories.

Electronic reproduction.
Amsterdam :
Elsevier Science & Technology,
2008.

Mode of access: World Wide Web.

ISBN: 9780123694485

Source: 114525:114618Elsevier Science & Technologyhttp://www.sciencedirect.comSubjects--Topical Terms:

306870
Antineoplastic agents
--Development.Index Terms--Genre/Form:

228523
Electronic books.

LC Class. No.: RS431.A64 / C36 2008eb

Dewey Class. No.: 616.994061

National Library of Medicine Call No.: 2008 A-287

Cancer drug design and discovery
LDR:03837cam 2200349Ia 4500 001 219474
003 OCoLC
005 20110630094749.0
006 m d
007 cr cn|
008 110902s2007 enkaf ob 001 0 eng d
020 $a 9780123694485
020 $a 0123694485
029 1 $a NZ1 $b 12541708
035 $a (OCoLC)228148277
035 $a ocn228148277
037 $a 114525:114618 $b Elsevier Science & Technology $n http://www.sciencedirect.com
040 $a OPELS $c OPELS
049 $a KMCA
050 1 4 $a RS431.A64 $b C36 2008eb
060 1 4 $a 2008 A-287
060 1 4 $a QV 269 $b N397c 2008
082 0 4 $a 616.994061 $2 22
245 0 0 $a Cancer drug design and discovery $h [electronic resource] / $c edited by Stephen Neidle.
250 $a 1st ed.
260 $a New York, NY : $c 2008. $b Academic Press,
300 $a xv, 473 p., [27] p. of plates : $b ill. (some col.) ; $c 27 cm.
504 $a Includes bibliographical references and index.
505 0 $a Section I. Basic Principles -- 1. Modern cancer drug discovery: Integrating targets, technologies and treatments -- 2. Preclinical pharmacology and in vivo models -- 3. Clinical trial designs for more rapid proof-of-principle and approval -- Section II. Methodology -- 4. Structural biology and anticancer drug design -- 5. Natural product chemistry and cancer drug discovery -- 6. Pharmacokinetics & ADME optimization in drug discovery -- Section III. Drugs in the clinic and laboratory -- 7. Temozolomide: from cytotoxic to molecularly-targeted agent -- 8. Camptothecins for drug design, cancer cell death and gene targeting -- 9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer -- Section IV. New Agents -- 10. Targeting inactive kinases: structure as a foundation for cancer drug discovery -- 11. Cell cycle inhibitors in cancer: current status and future directions -- 12. Inhibition of DNA repair as a therapeutic target -- 13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways -- 14. Heat shock protein-90-directed therapeutics and target validation -- 15. Inhibitors of tumour angiogenesis -- 16. The biology and oncology of RAFERK signalling P53 as a therapeutic target -- Section V. The reality of cancer drugs in the clinic -- 17. Cancer drug resistance -- 18. Failure Modes in Anticancer Drug Discovery and Development.
520 $a The ultimate source of information on the design of new anticancer agents, emphasising small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumours. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry, and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories.
533 $a Electronic reproduction. $b Amsterdam : $c Elsevier Science & Technology, $d 2008. $n Mode of access: World Wide Web. $n System requirements: Web browser. $n Title from title screen (viewed on May 14, 2008). $n Access may be restricted to users at subscribing institutions.
650 0 $a Antineoplastic agents $x Development. $3 306870
650 0 $a Antineoplastic agents $x Design. $3 306871
650 0 $2 96060 $a Cancer $x Chemotherapy. $3 237030
650 1 2 $2 96060 $a Antineoplastic Agents. $3 237031
650 2 2 $2 96060 $a Drug Design. $3 213976
650 2 2 $2 96060 $a Neoplasms $x drug therapy. $3 217582
655 7 $a Electronic books. $2 local $3 228523
700 1 $a Neidle, Stephen. $3 306869
710 2 $2 97100 $a ScienceDirect (Online service) $3 254190
856 4 0 $3 ScienceDirect $u http://www.sciencedirect.com/science/book/9780123694485 $z An electronic book accessible through the World Wide Web; click for information
994 $a 92 $b KMC